JP2002179579A - Method for biologically utilizing apoptosis-inducing polysaccharides - Google Patents

Method for biologically utilizing apoptosis-inducing polysaccharides

Info

Publication number
JP2002179579A
JP2002179579A JP2000379937A JP2000379937A JP2002179579A JP 2002179579 A JP2002179579 A JP 2002179579A JP 2000379937 A JP2000379937 A JP 2000379937A JP 2000379937 A JP2000379937 A JP 2000379937A JP 2002179579 A JP2002179579 A JP 2002179579A
Authority
JP
Japan
Prior art keywords
apoptosis
polysaccharide
cells
inducing
polysaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000379937A
Other languages
Japanese (ja)
Other versions
JP4991046B2 (en
Inventor
Koichi Okuya
康一 奥谷
Masahiro Matsuda
政広 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2000379937A priority Critical patent/JP4991046B2/en
Publication of JP2002179579A publication Critical patent/JP2002179579A/en
Application granted granted Critical
Publication of JP4991046B2 publication Critical patent/JP4991046B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a method for utilizing polysaccharides which are useful for inducing cell apoptosis and formed by microorganisms. SOLUTION: This method comprises utilizing a compound expressed by formula (I) or its salt as an apoptosis-inducing agent, wherein the compound comprises a polysaccharide obtained by subjecting Pseudomonas culture to separation and refinement. The polysaccharide is expected to be useful as a medicament, for example, as a remedy for malignant tumors, autoimmune diseases, and inflammations.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】 本発明は医薬の分野で有用
であり、より具体的には細胞の新陳代謝等に関係深いア
ポトーシス誘導剤としての多糖類の利用方法に関するも
のである。
TECHNICAL FIELD [0001] The present invention is useful in the field of medicine, and more specifically to a method of using a polysaccharide as an apoptosis inducer closely related to cell metabolism and the like.

【0002】[0002]

【従来の技術】 生物体を構成する細胞の死滅は、アポ
トーシス(apoptosis)とネクローシス(necrosis)の二つ
に大別される。ネクローシスは、環境の悪化又は細胞の
物理的障害により惹起される細胞死であり、一方、アポ
トーシスは、これと異なり、積極的に制御されている細
胞死のことである[ササダ(M.Sasada):血液フロンティ
ア, 10, 1367-1372(2000)参照]。
2. Description of the Related Art The death of cells constituting an organism is roughly classified into apoptosis and necrosis. Necrosis is cell death caused by aggravation of the environment or physical damage to cells, whereas apoptosis, by contrast, is actively regulated cell death [M. Sasada : Blood Frontier, 10, 1367-1372 (2000)].

【0003】近年、このアポトーシスによる細胞死が、
生物学、医学等の基礎研究分野、医薬品製造等の工業分
野において注目を集めている。その理由は、アポトーシ
スが胎生期の発達過程における形態器官形成、正常細胞
の回転、免疫系の構築と維持、ホルモンに依存した細胞
死制御などの生理的現象において、又病理的現象として
は放射線や薬物による細胞死、ウイルス感染による細胞
死など、さらに種々疾患との深い関連など極めて広範囲
かつ重要なことが明らかにされつつあること。各種の抗
がん剤がアポトーシスでがん細胞破壊を行うこと、及び
最近の遺伝子研究の進展に伴い、アポトーシスそのもの
がどのような遺伝子で制御されており、アポトーシスに
到る情報がどのようにして伝達されるかについての知見
が蓄積され、細胞生物学上の基本的興味がもたれたこ
と、等である[ムラテ(T.Murate):血液フロンティア、1
0, 1373-1381(2000)及びユオ(Yuo):血液フロンティア,
10, 1383-1395(2000)参照]。
In recent years, cell death due to this apoptosis has
It attracts attention in basic research fields such as biology and medicine, and in industrial fields such as pharmaceutical manufacturing. The reason is that apoptosis is a physiological phenomenon such as morphogenesis during embryonic development, normal cell rotation, immune system construction and maintenance, hormone-dependent cell death control, and pathological phenomena such as radiation and It is being clarified that it is extremely widespread and important, such as cell death due to drugs and cell death due to viral infection, as well as a deep relationship with various diseases. With the development of various anticancer drugs that cause cancer cell destruction by apoptosis, and the recent progress in genetic research, what kind of genes control apoptosis itself and how is the information leading to apoptosis? The accumulation of knowledge on whether or not it is transmitted has led to basic interests in cell biology, etc. [T. Murate: Blood Frontier, 1
0, 1373-1381 (2000) and Yuo: Blood Frontier,
10, 1383-1395 (2000)].

【0004】以上のような知見は、アポトーシスを誘導
することによって、その存在が生体にとって望ましくな
い細胞、例えば自己免疫疾患患者の自己反応性リンパ
球、アレルギー患者のアレルゲンに感作されたリンパ
球、がん細胞等を排除することが可能であることを示し
ており、そのためにアポトーシス誘導剤の果たす役割が
期待されている。又外部からの細菌やウイルスのアポト
ーシスを誘導することにより、細菌からの感染治療を促
したり、あるいは、皮膚の表皮細胞のアポトーシスを誘
導することにより皮膚の新陳代謝を促進することができ
ると考えられる。従って、アポトーシスを制御する因子
や薬剤を開発し、これらの疾患の治療に応用する可能性
を探る動きも起こってきている。しかし、その数はまだ
少なく、新たな化合物の提供が望まれている。
The above findings suggest that by inducing apoptosis, cells whose presence is undesirable in living organisms, such as autoreactive lymphocytes of patients with autoimmune diseases, lymphocytes sensitized to allergens of allergic patients, This indicates that cancer cells and the like can be eliminated, and for that purpose, a role of an apoptosis-inducing agent is expected. In addition, it is considered that by inducing apoptosis of bacteria and viruses from the outside, infection treatment from bacteria can be promoted, or metabolism of the skin can be promoted by inducing apoptosis of epidermal cells of the skin. Therefore, there has been a movement to develop factors and drugs that control apoptosis and explore the possibility of applying them to the treatment of these diseases. However, the number is still small and it is desired to provide new compounds.

【0005】このうち、多糖類に関係するものとして
は、例えばヘパリンがヒトリンパ芽球のアポトーシスを
強く誘導すること[エルドラン(E.Erduran)ら:American
Journal of Hematology, 61, 90-93(1999)参照]や、海
洋微細藻類の生産する硫酸多糖類がヒト白血病培養細胞
K562に対しいてアポトーシス誘導作用のあることが知ら
れている[ソガワ(K.Sogawa)ら:Journal of Marine Bio
technology, 6, 241-243(1998)参照]。
Among them, one related to polysaccharides is that heparin strongly induces apoptosis of human lymphoblasts [E. Erduran et al .: American
Journal of Hematology, 61, 90-93 (1999)], and sulfated polysaccharides produced by marine microalgae
It is known that K562 has an apoptosis-inducing action [K. Sogawa et al .: Journal of Marine Bio
technology, 6, 241-243 (1998)].

【0006】電子顕微鏡を用いた形態学的観察によれ
ば、アポトーシスによる細胞死では、染色体の凝集、細
胞核の断片化、細胞表面の微絨毛の消失、細胞質の凝縮
が観察され、アポトーシスにより死滅した細胞は、速や
かにマクロフアージ等に貪食されて処理されることが明
らかにされている。また、染色体DNAの断片化等の生化
学的特徴を伴うアポトーシスが観察されることが多いこ
とも良く知られている。
According to morphological observation using an electron microscope, cell death due to apoptosis was observed by apoptosis, including chromosome aggregation, fragmentation of the cell nucleus, loss of microvilli on the cell surface, and cytoplasmic condensation. It has been shown that cells are rapidly phagocytosed and processed by macrophages and the like. It is also well known that apoptosis accompanied by biochemical characteristics such as fragmentation of chromosomal DNA is often observed.

【0007】一方、構造式(I)で示される硫酸多糖類
は、海洋微生物の培養液から分離精製された化合物であ
り、ある主のウイルスに対して弱い抗ウイルス活性をを
示すことが知られている[マツダ(M.Matsuda)ら:日本水
産学会誌, 59, 535-538(1993)及びマツダ(M.Matsuda)
ら:Marine Biotechnology, 1, 68-73(1999)参照]。し
かしながら、その生物活性とくにアポトーシス誘導作用
を有することは知られておらず、文献にも記載されてい
ない。
On the other hand, the sulfated polysaccharide represented by the structural formula (I) is a compound separated and purified from a culture solution of a marine microorganism, and is known to exhibit weak antiviral activity against a certain major virus. Mazda (M.Matsuda et al .: Journal of the Fisheries Society of Japan, 59, 535-538 (1993) and Mazda (M.Matsuda)
Et al .: Marine Biotechnology, 1, 68-73 (1999)]. However, it is not known that it has a biological activity, particularly an apoptosis-inducing effect, and it is not described in the literature.

【0008】[0008]

【発明が解決しようとする課題】 本発明は、海洋微生
物の培養物から分離精製した多糖類をアポトーシス誘導
剤として開発し提供することを目的とする。
An object of the present invention is to develop and provide a polysaccharide separated and purified from a culture of a marine microorganism as an apoptosis inducer.

【0009】[0009]

【課題を解決するための手段】 本発明者等は、種々の
化合物について探索した結果、海洋微生物の生産する多
糖類にアポトーシスを誘導する作用を持つことを見出
し、本発明を完成した。
Means for Solving the Problems The present inventors have searched for various compounds, and as a result, have found that polysaccharides produced by marine microorganisms have an action of inducing apoptosis, and completed the present invention.

【0010】本発明で使用した多糖類は、文献[上記マ
ツダ(M.Matsuda)ら:1993] に記載されている硫酸多糖
類と同じもので、場合により薬理及び製薬上容認できる
その塩である。
The polysaccharide used in the present invention is the same as the sulfated polysaccharide described in the literature [M. Matsuda et al .: 1993, supra, and optionally a pharmaceutically and pharmaceutically acceptable salt thereof. .

【0011】即ち、本発明は上記構造式(I)で表される
多糖類又は生理学的に許容されうるその塩のアポトーシ
ス誘導剤としての利用に関するものである。
That is, the present invention relates to the use of a polysaccharide represented by the above structural formula (I) or a physiologically acceptable salt thereof as an apoptosis inducer.

【0012】[0012]

【発明の実施の形態】 本発明で使用する多糖類を生産
する能力のある微生物としては、海洋性シユードモナス
(Pseudomonas)属の微生物が挙げられ、より具体的には
シュードモナス・エスピー(Pseudomonas sp.)WAK-1が挙
げられる。本株は香川大学農学部生物資源食糧化学科松
田研究室に保存されている[マツダ(M.Matsuda)ら:日本
水産学会誌, 58, 1735-1741(1992)参照]。
BEST MODE FOR CARRYING OUT THE INVENTION As a microorganism capable of producing a polysaccharide used in the present invention, marine Pseudomonas
(Pseudomonas) microorganisms, and more specifically, Pseudomonas sp. WAK-1. This strain is stored in the Matsuda Laboratory, Department of Bioresources and Food Chemistry, Faculty of Agriculture, Kagawa University [see M. Matsuda et al .: Journal of the Fisheries Society of Japan, 58, 1735-1741 (1992)].

【0013】なお、該多糖類の生産株シュードモナス・
エスピー(Pseudomonas sp.)WAK-1に因んで、上記構造
式(I)で示される多糖類をを以下WAK-APOと称する。
The polysaccharide producing strain Pseudomonas
The polysaccharide represented by the above structural formula (I) based on Pseudomonas sp. WAK-1 is hereinafter referred to as WAK-APO.

【0014】海洋性シュードモナス(Pseudomonas)属の
菌株を栄養源含有培地に接種して発育させることによ
り、WAK-APOを含む培養物が得られる。培地は前記微生
物が資化できる炭素源、窒素源及び生育に必要な各種無
機塩等の栄養源を含む液体培地が好ましい。具体的に
は、例えば、炭素源としては、グルコース、フラクトー
ス、シュクロース等が挙げられ、単独又は混合物として
用いられる。窒素源としては、肉エキス、酵母エキス、
ポリペプトン、その他の有機物あるいは無機物等が挙げ
られ、単独又は混合物として用いられる。無機塩として
は、炭酸カルシウム、塩化ナトリウム、又は各種リン酸
塩等を使用することができる。その他、必要に応じて、
鉄、マンガン、亜鉛、コバルト等の重金属塩を微量添加
することもできる。また、海水で調製した培地が好まし
いが、人工海水や2〜3重量%の食塩水でも良い。
A culture containing WAK-APO can be obtained by inoculating a marine Pseudomonas strain into a nutrient-containing medium and growing it. The medium is preferably a liquid medium containing nutrients such as a carbon source and a nitrogen source which can be assimilated by the microorganism and various inorganic salts necessary for growth. Specifically, for example, as the carbon source, glucose, fructose, sucrose and the like can be mentioned, and these are used alone or as a mixture. Nitrogen sources include meat extract, yeast extract,
Polypeptone, other organic or inorganic substances, and the like are used, and they are used alone or as a mixture. As the inorganic salt, calcium carbonate, sodium chloride, various phosphates and the like can be used. In addition, if necessary,
Trace amounts of heavy metal salts such as iron, manganese, zinc, and cobalt can also be added. Further, a medium prepared with seawater is preferable, but artificial seawater or a 2 to 3% by weight saline solution may be used.

【0015】培養方法としては、一般の微生物の代謝産
物生産方法と同様に行えばよく、固体培養でも液体培養
でも良いが、液体培養がより好ましい。液体培養の場合
は、攪拌培養、振盪培養又は通気培養等のいずれを実施
しても良いが、実質的に振盪の条件で培養すれば、培養
物中に本発明で使用する硫酸多糖類が選択的に生成蓄積
する(特願2000-265079参照)。発泡の激しい場合には、
消泡剤として例えば大豆油等の植物油、オクタデカノー
ル等の高次アルコール類、各種シリコン化合物等を適宜
添加しても良い。
The culturing method may be the same as the method for producing a metabolite of a general microorganism, and may be either solid culture or liquid culture, but liquid culture is more preferable. In the case of liquid culture, any of stirring culture, shaking culture, aeration culture, etc. may be performed, but if cultured under substantially shaking conditions, the sulfated polysaccharide used in the present invention is selected in the culture. (See Japanese Patent Application No. 2000-265079). If foaming is severe,
As an antifoaming agent, for example, vegetable oils such as soybean oil, higher alcohols such as octadecanol, various silicon compounds and the like may be appropriately added.

【0016】培養は通常pHは6.0〜8.0、好ましくは6.5
〜7.5の範囲で、温度は15〜35℃、好ましくは25〜30℃
が適当である。培養時間は本発明で用いる多糖類の生産
が最大に達する期間が選ばれるが、通常は48〜144時
間、好ましくは72〜96時間である。
The cultivation usually has a pH of 6.0 to 8.0, preferably 6.5.
In the range of ~ 7.5, the temperature is 15 ~ 35 ° C, preferably 25 ~ 30 ° C
Is appropriate. The cultivation time is selected to be a period in which the production of the polysaccharide used in the present invention is maximized, but is usually 48 to 144 hours, preferably 72 to 96 hours.

【0017】このようにして得られた培養物中には、本
発明で使用する多糖類が含まれている。該多糖類の採取
に当たっては、WAK-APOは菌体外に存在するので、予め
培養物中の菌体や他の固形成分を除去した後、通常の分
離手段、例えば溶媒沈殿法、イオン交換樹脂法又は吸着
若しくは分配クロマトグラフィー法及びゲル濾過法、透
析、凍結乾燥法等多糖類を不純物から回収するために通
常使用されている手段を単独にあるいは適宜組み合わせ
ることによって分離精製できる。
The thus obtained culture contains the polysaccharide used in the present invention. In collecting the polysaccharide, WAK-APO is extracellular, so after removing cells and other solid components in the culture in advance, ordinary separation means, for example, solvent precipitation, ion exchange resin, etc. Separation and purification can be carried out by a method generally used for recovering polysaccharides from impurities, such as a method or adsorption or partition chromatography, gel filtration, dialysis, and freeze-drying, alone or in an appropriate combination.

【0018】その一例を示すと、上記固形分を除去して
得られた溶液にエタノール等の溶剤を添加して該多糖類
を析出せしめる。得られた該多糖類を水に溶解させ、こ
れに第四級アンモニウム塩例えばセチルトリメチルアン
モニウムブロマイド溶液を加えてセチルトリメチルアン
モニウムブロマイドとの複合体として多糖類を沈殿させ
る。この沈殿物を塩化ナトリウムを含む水に溶解させた
後、エタノールによる沈殿を行い、沈殿物を水に溶解さ
せた後、透析、凍結乾燥することにより該多糖類を得る
ことができる。
As an example, a solvent such as ethanol is added to a solution obtained by removing the solid content to precipitate the polysaccharide. The obtained polysaccharide is dissolved in water, and a quaternary ammonium salt such as cetyltrimethylammonium bromide solution is added thereto to precipitate the polysaccharide as a complex with cetyltrimethylammonium bromide. The polysaccharide can be obtained by dissolving the precipitate in water containing sodium chloride, precipitating with ethanol, dissolving the precipitate in water, dialysis and freeze-drying.

【0019】このようにして得られた多糖類について
は、DEAE-セルロースイオン交換カラムクロマトグラフ
ィー、電気泳動法による均一性分析、糖組成分析、硫酸
基分析、及び核磁気共鳴分析等により、目的とする多糖
類であることが確認できる[上記マツダ(M.Matsuda)ら、
(1993)参照]。
The polysaccharide thus obtained is analyzed by DEAE-cellulose ion-exchange column chromatography, homogeneity analysis by electrophoresis, sugar composition analysis, sulfate group analysis, nuclear magnetic resonance analysis, and the like. [Mazda (Matsuda) et al.,
(1993)].

【0020】得られた多糖類を試験試料としてヒト骨髄
性白血病細胞U937を用いてアポトーシス誘導試験を細胞
の形態変化と、DNAの断片化分析とにより試験を実施す
る。
Using the obtained polysaccharide as a test sample, an apoptosis induction test is performed by using human myeloid leukemia cells U937 by a cell morphological change and DNA fragmentation analysis.

【0021】[0021]

【実施例】 以下に、参考例、試験例を挙げて本発明を
具体的に説明するが、本発明は実施例のみに限定される
ものではない。参考例 文献[マツダ(M.Matsuda)ら: 1
992]の記載に従い、ペプトン0.5%、酵母エキス0.1%、の
組成を有する海水から調製した培地を、121℃にて20分
間オートクレーブで滅菌した。シュードモナス・エスピ
ーWAK-1(Pseudomonas sp.WAK-1,香川大学農学部生物資
源食糧化学科松田研究室保存菌株No.WAK-1)の保存用斜
面培養から1白金耳を試験管中の上記滅菌培地(10mL)に
接種し、28℃にて72時間振盪培養をおこなった。つい
で、この前培養液を500mL容の三角フラスコ中の3%ショ
糖加上記滅菌培地(200mL)に接種し、28℃にて72時間振
盪培養を行った。培養後、培養終了液を遠心分離して菌
体を除いた上澄液に2倍量のエタノールを加え、白色沈
殿を得た。この沈殿物を採取し、水(200mL)中に溶解
し、沈殿が新たに生じなくなるまで5%セチルトリメチル
アンモニウムブロマイド水溶液を徐々に加え、セチルト
リメチルアンモニウムブロマイドとの複合体として多糖
類を沈殿させた。この複合体を水で洗浄して過剰のセチ
ルトリメチルアンモニウムブロマイドを除いた後、4M塩
化ナトリウム水溶液(200ml)中に複合体を溶解した。こ
の溶液に、2倍量のエタノールを加えて多糖類を沈殿さ
せた。得られた沈殿物を水に溶解し、水に対して透析
後、凍結乾燥を行い、酸性多糖類(約0.1g)を得た。本多
糖類をさらに精製するため、次にこの多糖類(102mg)を
0.01Mリン酸塩緩衝液(pH7.0)100mLに溶解し0.01Mリン酸
緩衝液(pH7.0)で平衡させたDEAE-セルロースカラム(2.3
×22.5cm)に充填した。0.01Mリン酸緩衝液(pH7.0)中の
0.6M塩化ナトリウムで溶出される画分を除いた後、0.8M
塩化ナトリウムで溶出される画分を集め、透析し、次い
で凍結乾燥し多糖類(53mg)を得た。このようにして得ら
れた多糖類については、セルロースアセテート膜電気泳
動法を用いて均一性を確認すると共に、糖組成分析、硫
酸基含量分析、及び核磁気共鳴分析等により、構造式
(I)で示される多糖類であることを確認した[上記マツダ
(M.Matsuda)ら:(1993)参照]。
EXAMPLES Hereinafter, the present invention will be described specifically with reference to Reference Examples and Test Examples, but the present invention is not limited to Examples. Reference example Reference [M.Matsuda et al .: 1
992], a medium prepared from seawater having a composition of peptone 0.5% and yeast extract 0.1% was sterilized in an autoclave at 121 ° C. for 20 minutes. Pseudomonas sp. WAK-1 (Pseudomonas sp. (10 mL), and cultured with shaking at 28 ° C. for 72 hours. Then, the preculture solution was inoculated into the above sterilized medium (200 mL) containing 3% sucrose in a 500 mL Erlenmeyer flask, and cultured at 28 ° C. for 72 hours with shaking. After the culture, the culture-finished solution was centrifuged to remove the cells, and twice the amount of ethanol was added to the supernatant to obtain a white precipitate. The precipitate was collected, dissolved in water (200 mL), and a 5% cetyltrimethylammonium bromide aqueous solution was gradually added until no new precipitate was formed, to precipitate a polysaccharide as a complex with cetyltrimethylammonium bromide. . After washing the complex with water to remove excess cetyltrimethylammonium bromide, the complex was dissolved in a 4M aqueous sodium chloride solution (200 ml). To this solution, twice the amount of ethanol was added to precipitate the polysaccharide. The obtained precipitate was dissolved in water, dialyzed against water, and lyophilized to obtain an acidic polysaccharide (about 0.1 g). This polysaccharide (102 mg) was then purified to further purify the polysaccharide.
A DEAE-cellulose column (2.3
× 22.5 cm). In 0.01 M phosphate buffer (pH 7.0)
After removing the fraction eluted with 0.6M sodium chloride, 0.8M
Fractions eluted with sodium chloride were collected, dialyzed, and lyophilized to give the polysaccharide (53 mg). The polysaccharide obtained in this manner was checked for homogeneity using cellulose acetate membrane electrophoresis, and analyzed for sugar composition, sulfate group content, and nuclear magnetic resonance.
(I) was confirmed to be a polysaccharide represented by
(M. Matsuda) et al. (1993)].

【0022】次に、上記で得られたWAK-APOについて本
発明の効果を確認するため、以下の試験を行った。アポ
トーシス誘導作用を検出する際には、細胞壊死であるネ
クローシスとの違いを明らかにする必要がある。アポト
ーシスが誘導された細胞は、上述したように、先ず細胞
が縮小し、クロマチンが凝縮し、凝縮した核は断片化す
る。また、細胞表面の微絨毛は消失して平滑化し、自己
認識機構を担う細胞表面分子マーカーを徐々に喪失して
いく。さらに、細胞表面に大小の突起が出現し、やがて
アポトーシス小体に断片化する。このアポトーシス小体
は、生体内においてはやがてマクロファージのような貪
食細胞によって除去される。
Next, the following test was conducted to confirm the effects of the present invention on the WAK-APO obtained above. When detecting the apoptosis-inducing action, it is necessary to clarify the difference from necrosis, which is cell necrosis. As described above, the cells in which apoptosis is induced first shrink, the chromatin is condensed, and the condensed nuclei are fragmented. In addition, the microvilli on the cell surface disappear and become smooth, and the cell surface molecular markers responsible for the self-recognition mechanism are gradually lost. In addition, large and small protrusions appear on the cell surface and eventually fragment into apoptotic bodies. These apoptotic bodies are eventually eliminated in vivo by phagocytic cells such as macrophages.

【0023】そこでこれらの現象に着目して、ヒト骨髄
性白血病細胞U937にWAK-APOを添加し、反応終了後、ア
ポトーシスが誘導されたかどうかを検出するため、以下
のような複数の方法を用いて実験を行った。
Therefore, paying attention to these phenomena, WAK-APO was added to human myeloid leukemia cells U937, and after the reaction was completed, a plurality of methods described below were used to detect whether apoptosis was induced. Experiments.

【0024】試験例 ヒト培養細胞に対する前記参考例
で得たWAK-APOのアポトーシス誘導効果を試験管内で試
験した。培養細胞にはヒト単球系白血病細胞U937を用い
た。培地は、10%FBSを含むRPMIを用いた。細胞の前培養
を行い、対数期に入った細胞を3×105個/mLになるよう
に培地で調整し、24穴培養プレートに1mLずつ分注し、
サンプル溶液を10μLずつ最終濃度が、それぞれ10, 1,
0.1, 0.01μg/mLになるように添加し、混和した。培養
は、37℃、5%炭酸ガス濃度で行い、 24時間培養した
後、各ウエルの細胞について形態変化を顕微鏡写真撮影
し観察すると共に、アガロース電気泳動法でDNA断片化
分析を行った。
Test Example The apoptosis-inducing effect of WAK-APO obtained in the above Reference Example on human cultured cells was tested in vitro. Human monocyte leukemia cells U937 were used as cultured cells. The medium used was RPMI containing 10% FBS. Preculture the cells, adjust the cells in the log phase to 3 × 105 cells / mL with a medium, and dispense 1 mL each into a 24-well culture plate,
The final concentration of 10 μL of the sample solution was 10, 1, respectively.
0.1 and 0.01 μg / mL were added and mixed. The cells were cultured at 37 ° C. and 5% CO 2 concentration for 24 hours. After culturing for 24 hours, the morphological changes of the cells in each well were photographed and observed, and DNA fragmentation analysis was performed by agarose electrophoresis.

【0025】形態変化の観察では、形態変化の全くない
ものを(-)、多くの細胞に形態変化が認められるものを
(+)、細胞が死滅していると思われるものを(++)と判定
し、又DNA 断片化分析 では、DNA ladderが見られない
ものを(-)、DNAの分解が認められるものを(+)とし、DNA
ladderがはっきり見られるものを(++)と判定した。試
験結果を表1に示す。
In the observation of the morphological change, those with no morphological change (-) and those with morphological change observed in many cells were identified.
(+), Cells that seemed dead were judged as (++), and DNA fragmentation analysis showed no DNA ladder (-), while DNA degradation was observed. (+) And DNA
The one with a clear ladder was judged as (++). Table 1 shows the test results.

【0026】[0026]

【表1】 [Table 1]

【0027】表1に示すように、コントロールにおいて
は、形態変化、DNAの断片化は見られなかったが、WAK-A
POで処理したU937細胞には0.1, 1μL/mLの濃度でアポト
ーシスに特徴的な細胞の形態変化が認められた。又0.1,
1μL/mLの濃度で断片化したDNAからなる梯子状の泳動
像が見られ、アポトーシスの特徴であるDNAの断片化が
観察された。
As shown in Table 1, no morphological change or DNA fragmentation was observed in the control, but WAK-A
In U937 cells treated with PO, cell morphological changes characteristic of apoptosis were observed at concentrations of 0.1 and 1 μL / mL. 0.1
A ladder-like electrophoresis image composed of DNA fragmented at a concentration of 1 μL / mL was observed, and DNA fragmentation characteristic of apoptosis was observed.

【0028】以上の試験結果が示すように、本参考例で
製造したWAK-APOにはアポトーシス誘導作用があること
が認められた。
As shown by the above test results, it was confirmed that WAK-APO produced in this Reference Example had an apoptosis-inducing effect.

【0029】[0029]

【発明の効果】 本発明に記載する多糖類WAK-APOは、
ヒト培養細胞に対してアポトーシス誘導作用を示すこと
から、細胞サイクルを制御することが可能であり、医
薬、例えば悪性腫瘍、自己免疫疾患、炎症等の治療薬と
しての用途が期待できる。
The polysaccharide WAK-APO described in the present invention comprises:
Since it exhibits an apoptosis-inducing effect on cultured human cells, it can control the cell cycle, and can be expected to be used as a drug, for example, a therapeutic drug for malignant tumors, autoimmune diseases, inflammation, and the like.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) // C08B 37/00 C08B 37/00 H ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) // C08B 37/00 C08B 37/00 H

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】有効成分が構造式(I)で示される化合物又
はその塩類のアポトーシス誘導剤としての利用方法。 【化1】
[1] A method of using a compound represented by the structural formula (I) or a salt thereof as an apoptosis-inducing agent as an active ingredient. Embedded image
JP2000379937A 2000-12-14 2000-12-14 Apoptosis inducer Expired - Fee Related JP4991046B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000379937A JP4991046B2 (en) 2000-12-14 2000-12-14 Apoptosis inducer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000379937A JP4991046B2 (en) 2000-12-14 2000-12-14 Apoptosis inducer

Publications (2)

Publication Number Publication Date
JP2002179579A true JP2002179579A (en) 2002-06-26
JP4991046B2 JP4991046B2 (en) 2012-08-01

Family

ID=18848212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000379937A Expired - Fee Related JP4991046B2 (en) 2000-12-14 2000-12-14 Apoptosis inducer

Country Status (1)

Country Link
JP (1) JP4991046B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003023045A1 (en) * 2001-09-06 2003-03-20 Techno Network Shikoku Co.,Ltd. Sulfated polysaccharides, process for producing the same and substances having the same as the active ingredient
JP2006016336A (en) * 2004-07-01 2006-01-19 Shiibaion:Kk Macrophage-activating agent having il-12 production-inducing activity
JP2006062983A (en) * 2004-08-24 2006-03-09 Kyoto Sangyo Univ Composition and antitumor agent containing the same
JP2016501526A (en) * 2012-12-06 2016-01-21 エンリヴェックス セラピューティクス リミテッド A therapeutic apoptotic cell preparation, its production method and its use

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003023045A1 (en) * 2001-09-06 2003-03-20 Techno Network Shikoku Co.,Ltd. Sulfated polysaccharides, process for producing the same and substances having the same as the active ingredient
JP2006016336A (en) * 2004-07-01 2006-01-19 Shiibaion:Kk Macrophage-activating agent having il-12 production-inducing activity
JP2006062983A (en) * 2004-08-24 2006-03-09 Kyoto Sangyo Univ Composition and antitumor agent containing the same
JP2016501526A (en) * 2012-12-06 2016-01-21 エンリヴェックス セラピューティクス リミテッド A therapeutic apoptotic cell preparation, its production method and its use
US10077426B2 (en) 2012-12-06 2018-09-18 Enlivex Therapeutics Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof
JP2019047813A (en) * 2012-12-06 2019-03-28 エンリヴェックス セラピューティクス リミテッド Therapeutic apoptotic cell preparations, method for producing the same and uses thereof
US10927343B2 (en) 2012-12-06 2021-02-23 Enlivex Therapeutics Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof

Also Published As

Publication number Publication date
JP4991046B2 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
CN109970538B (en) Sesquiterpenoids derived from marine fungi, preparation method thereof and application thereof in preparing anti-inflammatory drugs
EP1954800A2 (en) Composition and use of phyto-percolate for treatment of disease
Akhter et al. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system
CN106727623B (en) Application of seaweed oligosaccharide in preparation of anti-avian leukosis virus preparation
SU1423002A3 (en) Method of producing protein reducing content of cholesterol in blood of mammals
JP4991046B2 (en) Apoptosis inducer
CN109022309B (en) Stenotrophomonas maltophilia capable of producing free fatty acid and application thereof
CN108864316B (en) Sulfonated peony seed polysaccharide and application thereof in preparation of auxiliary medicine for treating liver cancer
CN116284479A (en) Sparassis crispa polysaccharide, and preparation method and application thereof
Sun et al. Effects of AZT and RNA-protein complex (FA-2-b-β) extracted from Liang Jin mushroom on apoptosis of gastric cancer cells
RU2177788C2 (en) Preparation to prevent and treat infectious diseases and correct pathological states
CN112843026A (en) Application of diphenyl ether compound in preparation of acetylcholinesterase inhibitor or medicament for treating Alzheimer disease
US5711948A (en) Plant-derived, biologically active polysaccharides and method of preparing same
JPH04300898A (en) New glycoprotein conjugate and production thereof
US3629235A (en) Process for isolating an interferon inducer and the product per se
RU2610446C2 (en) Preparation, increasing production of nitrogen oxide by macrophages in vitro, based on humic acids of peat of tomsk region bogs and method for obtaining thereof
CN114940679B (en) STING agonist prodrug compound, preparation method and application thereof
CN113181222B (en) Application of extracellular polysaccharide metabolite of cryptococcus lactis in preparation of antiviral drugs
CN116694485B (en) Application of colletotrichum gloeosporioides and extracellular polysaccharide thereof as plant immunity elicitor
CN112759661B (en) Cherokee rose fruit polysaccharide preparation method, identification method and application
RU2422532C2 (en) Method of recovery low-molecular nuclear ribonucleoproteids (rnp) from tissues and organs of mammals
CN105754931A (en) Method for promoting human keratinocytes to activate TNF (tumor necrosis factor) signal pathways
RU2435611C1 (en) Method for producing polymeric complex
CN104926932B (en) The polypeptide extracted in a kind of nematoblast venom from fire medusa and its application
RU2412995C1 (en) Method of obtaining collagenase inhibitor with anti-tumour action from hepatopancreas of red king crab

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071023

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20071023

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071114

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110426

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110705

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120424

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120507

R150 Certificate of patent or registration of utility model

Ref document number: 4991046

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees